7.1 Mandatory Interchange & the Massachusetts List of Interchangeable Drug Products
Key Takeaways
- M.G.L. c. 112, § 12D makes interchange mandatory: the pharmacist shall dispense an interchangeable abuse-deterrent product if one exists, and if none exists a less expensive, reasonably available interchangeable drug product.
- A prescriber blocks interchange by indicating 'no substitution' on the prescription; the statute expressly provides that 'no substitution' shall not be the default setting on a prescription form or e-prescribing system.
- When an interchange is made the pharmacist must show it on the label in the form 'Interchange (name of exact drug product dispensed)'.
- The Massachusetts List of Interchangeable Drug Products is maintained by DPH at 105 CMR 720.000 and incorporates the FDA Orange Book together with an Additional List and an Exception List.
- For a narrow therapeutic index immunosuppressant dispensed to an organ transplant patient covered by MassHealth, the pharmacist must notify the prescribing physician when a substitution is made.
Mandatory Interchange & the Massachusetts List of Interchangeable Drug Products
Massachusetts does not merely permit generic substitution. It mandates interchange, and it uses the word interchange rather than substitution throughout.
The Statutory Mandate — M.G.L. c. 112, § 12D
The operative direction is a two-step hierarchy:
The pharmacist shall dispense: an interchangeable abuse-deterrent product if one exists; or, if none exists, a less expensive, reasonably available, interchangeable drug product.
[!IMPORTANT] The abuse-deterrent step comes first, and price comes second. Massachusetts added the abuse-deterrent priority as an opioid-crisis measure. Where an interchangeable abuse-deterrent formulation exists, it is dispensed — the cheaper non-abuse-deterrent interchangeable does not win. Only when no interchangeable abuse-deterrent product exists does the ordinary "less expensive, reasonably available, interchangeable" rule operate.
Blocking interchange
The prescriber prevents interchange by indicating "no substitution" on the prescription. Two features of the statute matter:
- The phrase is "no substitution." Language such as "brand medically necessary" is Medicaid/MassHealth brand-override vocabulary and serves a different purpose — it justifies payment for a brand product, not the blocking of interchange under § 12D.
- "No substitution" shall not be the default. The statute directs that prescriptions state that interchange is mandated unless the practitioner indicates "no substitution." A prescription form or e-prescribing system that pre-selects "no substitution" for every prescription does not comply, and a pharmacist should treat a system-wide default as what it is — a configuration artefact rather than a prescriber decision — and clarify.
The label entry
When an interchange is made, the pharmacist must indicate the fact of the interchange on the label in this form:
"Interchange (name of exact drug product dispensed)"
This is a Massachusetts-specific labelling requirement with no federal counterpart, and it pairs with the requirement in 247 CMR 9.04 to record the NDC of the product actually dispensed when a generic is supplied. Together they make every interchange auditable from the label back to the specific product.
Narrow therapeutic index immunosuppressants
For a narrow therapeutic index immunosuppressant dispensed to an organ transplant patient covered by MassHealth, the pharmacist shall notify the prescribing physician when a substitution is made. This is the one product class in which § 12D imposes an affirmative prescriber-notification duty.
The Massachusetts List of Interchangeable Drug Products (MLIDP)
The MLIDP is maintained by the Department of Public Health under 105 CMR 720.000, and every pharmacy must keep a current copy or electronic access to it under 247 CMR 9.19. It has three components:
| Component | What it contains |
|---|---|
| The Orange Book | The FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, incorporated as the baseline |
| The Additional List | Products DPH has determined to be interchangeable in Massachusetts beyond the Orange Book listing |
| The Exception List | Products that may not be interchanged in Massachusetts notwithstanding an Orange Book rating |
[!WARNING] The Exception List is the reason "check the Orange Book" is not a complete answer in Massachusetts. A product may carry an A rating federally and still sit on the Massachusetts Exception List. The MLIDP governs, and the pharmacy is required by 247 CMR 9.19 to hold a current copy precisely so that this can be checked.
FDA Therapeutic Equivalence Codes
The Orange Book code system underlies the whole scheme. Therapeutic equivalence = pharmaceutical equivalence + bioequivalence.
| Code | Meaning |
|---|---|
| A | Considered therapeutically equivalent to the reference listed drug |
| AA | Conventional oral dosage forms with no bioequivalence issues |
| AB | Bioequivalence demonstrated by testing; the most common code |
| AN | Solutions and powders for aerosolisation |
| AO | Injectable oil solutions |
| AP | Injectable aqueous solutions |
| AT | Topical products |
| B | Not therapeutically equivalent — actual or potential bioequivalence problems |
| BX | Data insufficient to determine therapeutic equivalence |
AB sub-codes. Where a drug has multiple reference listed products, the Orange Book appends a number — AB1, AB2, AB3. Products are interchangeable only within the same sub-code. An AB1 product substitutes for an AB1 product, not for an AB2 product.
Interchangeable Biological Products
Biological products appear in the FDA Purple Book rather than the Orange Book.
- A biosimilar is highly similar to the reference product with no clinically meaningful differences in safety, purity and potency.
- An interchangeable biological product meets the additional statutory standard and is the only category a pharmacist may substitute without prescriber intervention.
A biosimilar that is not designated interchangeable requires a new prescriber order. Pharmacists should verify the current Purple Book designation and any prescriber-communication requirements that apply to biological substitution before dispensing, rather than assuming that the small-molecule interchange rules transfer.
Worked Traps
- A prescription arrives from an e-prescribing system on which every prescription is flagged "no substitution." The statute says "no substitution" shall not be the default. Clarify with the prescriber rather than treating the flag as a decision.
- An interchangeable abuse-deterrent formulation exists but costs more than a plain interchangeable generic. Dispense the abuse-deterrent product. The hierarchy in § 12D puts it first.
- A generic is dispensed and the label reads only "Amoxicillin 500 mg." Non-compliant — the label must show "Interchange (name of exact drug product dispensed)."
- A MassHealth transplant patient receives an interchanged narrow therapeutic index immunosuppressant and no one calls the prescriber. Violation of the notification duty in § 12D.
Under M.G.L. c. 112, § 12D, what must a Massachusetts pharmacist dispense when an interchangeable abuse-deterrent product and a cheaper interchangeable non-abuse-deterrent product both exist?
A Massachusetts pharmacist interchanges a generic for a prescribed brand product. What must appear on the container label?
Why is checking only the FDA Orange Book insufficient before interchanging a product in Massachusetts?